Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixo-vec in Neovascular Age-related Macular Degeneration (AQUARIUS)
NCT07482176Phase 3Recruiting
- Sponsor
- Adverum Biotechnologies
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixoberogene soroparvovec in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Adverum Biotechnologies. Primary endpoint: Best Corrected Visual Acuity at 56 weeks. Started Mar 2026; status: recruiting.
02
Drugs
ixoberogene soroparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07482176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482176.